Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
MBX Biosciences, Inc. (MBX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
2Distinct source URLs
3High confidence
0.727Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
MBX Biosciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
INDIANA-UNIVERSITY-RESEARCH-AND-TECHNOLOGY-CORPO
INDIANA-UNIVERSITY-RESEARCH-AND-TECHNOLOGY-CORPO
92%
In the year ended December 31, 2025, the Company paid a $ 1.0 million milestone payment to IURTC related to the initiation of the Phase 1 clinical trial of MBX 4291.
Reciprocal relationship from SEPN graph: Reciprocal relationship from MBX graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from MBX graph: Reciprocal relationship from SEPN gra…
MBX Biosciences, Inc. Customers
Ticker
Name
Confidence
Evidence
BURLINGTON-WOODS-LLC
BURLINGTON-WOODS-LLC
62%
ncome, net Interest and other income, net, which includes interest income and amortization of premiums and discounts on our investments in marketable securities, were $3.7 million for the three month…
INDIANA-UNIVERSITY-RESEARCH-AND-TECHNOLOGY-CORPO
INDIANA-UNIVERSITY-RESEARCH-AND-TECHNOLOGY-CORPO
62%
es, intellectual property and technologies; • confirm, maintain or obtain freedom to operate for any of our owned or licensed technologies and product candidates; • establish and maintain collaborati…
Reciprocal relationship from JEF graph: Reciprocal relationship from MBX graph: FINANCIAL STATEMENTS 1. NATURE OF BUSINESS AND Liquidity MBX Biosciences, Inc. (“MBX” or the “Company”) is a clinical-s…
JEFFERIES-LLC
JEFFERIES-LLC
62%
FINANCIAL STATEMENTS 1. NATURE OF BUSINESS AND Liquidity MBX Biosciences, Inc. (“MBX” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel…
LIMITED-LIABILITY-COMPANY
LIMITED-LIABILITY-COMPANY
62%
FINANCIAL STATEMENTS 1. NATURE OF BUSINESS AND Liquidity MBX Biosciences, Inc. (“MBX” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel…
MBX Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
MBX-DEBT
Debt stack $555,000
90%
Market cache reports total debt of $555,000.
MBX Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for MBX Biosciences, Inc..
MBX Biosciences, Inc. Ownership
Holder
Name
Confidence
Evidence
MBX-OWNER-FRAZIER-LIFE-SCIENCES-MANAGEMENT
Frazier Life Sciences Management, L.P.
90%
13F overlay lists Frazier Life Sciences Management, L.P. as top holder; 159 tracked holders.
MBX Biosciences, Inc. Extended Supply Chain Network
